ArticleVirology2015
Recombinant Marburg viruses containing mutations in the IID region of VP35 prevent inhibition of Host immune responses.
Article in Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Development and characterization of a recombinant Bundibugyo virus expressing a fluorescent reporter protein.Emerging microbes & infections · 2026Article
- 25 Years of Ebola Virus VP35 Research.Journal of molecular biology · 2025Review
- Marburg and Sudan viruses elicit divergent interferon responses and cytokine storm signaling in Egyptian rousette bat macrophages.Frontiers in immunology · 2025Article
- Recovery of Recombinant Marburg Virus by Reverse Genetics.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Human macrophages infected with Egyptian Rousette bat-isolated Marburg virus display inter-individual susceptibility and antiviral responsiveness.Npj viruses · 2024Article
- Designing of a Multi-epitope Vaccine against the Structural Proteins of Marburg Virus Exploiting the Immunoinformatics Approach.ACS omega · 2021Article
- Effects of Overexpression of the Egyptian Fruit Bat Innate Immune Genes on Filovirus Infections in the Host Cells.Frontiers in virology (Lausanne, Switzerland) · 2021Article
- High-Throughput Screening Assay to Identify Small Molecule Inhibitors of Marburg Virus VP40 Protein.ACS infectious diseases · 2020Article
- Recent advances in marburgvirus research.F1000Research · 2019Review
- Article
- Conservation of Structure and Immune Antagonist Functions of Filoviral VP35 Homologs Present in Microbat Genomes.Cell reports · 2018Article
- Transcriptional analysis of viral mRNAs reveals common transcription patterns in cells infected by five different filoviruses.PloS one · 2018Article
- Molecular pathogenesis of viral hemorrhagic fever.Seminars in immunopathology · 2017Review
- Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions.Journal of virology · 2017Article
- VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability.Journal of virology · 2017Article
- Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system.Virology · 2017Article
- Marburg Virus Reverse Genetics Systems.Viruses · 2016Review
- Effects of Filovirus Interferon Antagonists on Responses of Human Monocyte-Derived Dendritic Cells to RNA Virus Infection.Journal of virology · 2016Article
- Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.Cell reports · 2016Article
- Immunological features underlying viral hemorrhagic fevers.Current opinion in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Previous in vitro studies have demonstrated that Ebola and Marburg virus (EBOV and MARV) VP35 antagonize the host cell immune response. Moreover, specific mutations in the IFN inhibitory domain (IID) of EBOV and MARV VP35 that abrogate their interaction with virus-derived dsRNA, lack the ability to inhibit the host immune response. To investigate the role of MARV VP35 in the context of infectious virus, we used our reverse genetics system to generate two recombinant MARVs carrying specific mutations in the IID region of VP35. Our data show that wild-type and mutant viruses grow to similar titers in interferon deficient cells, but exhibit attenuated growth in interferon-competent cells. Furthermore, in contrast to wild-type virus, both MARV mutants were unable to inhibit expression of various antiviral genes. The MARV VP35 mutants exhibit similar phenotypes to those previously described for EBOV, suggesting the existence of a shared immune-modulatory strategy between filoviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.